US · AEHR · SEMICONDUCTORS
Aehr Test Systems (AEHR) intrinsic value and stock valuation
$39.84as of 2026-11-21 · Mkt cap 3.36B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Aehr Test Systems DCF and intrinsic value
InvestorsCraft values AEHR with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AEHR’s statements →
Aehr Test Systems Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $50M | $59M | $66.2M | $65M | $50.8M |
| Operating income | -$-14.15M | -$-4.31M | $10.1M | $13.4M | $7.8M |
| Net income | -$-7.13M | -$-3.91M | $33.2M | $14.6M | $9.45M |
| EPSd | -$-232.47K | -$-132.18K | $1.12M | $498.5K | $340.3K |
| Operating cash flow | -$-3.31M | -$-7.4M | $1.76M | $10M | $1.51M |
| Capital expenditure | -$-2.07M | -$-4.99M | -$-750K | -$-1.36M | -$-420K |
| Free cash flow | -$-5.38M | -$-12.39M | $1.01M | $8.65M | $1.09M |
| Total assets | $246.7M | $148.5M | $127.9M | $98.1M | $62.3M |
| Total debt | $9.88M | $10.8M | $6.2M | $6.3M | $1.01M |
| Net debt | -$-106.48M | -$-14.4M | -$-42.96M | -$-23.75M | -$-30.48M |
| Total equity | $219.5M | $122.9M | $111.6M | $75.6M | $51M |
| Cash and short-term investments | $116.4M | $25.2M | $49.2M | $47.9M | $31.5M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $50M | $59M | $66.2M | $65M | $50.8M |
| Cost of revenue | $32.4M | $35M | $33.7M | $32.2M | $27.2M |
| Gross profit | $17.7M | $23.9M | $32.5M | $32.8M | $23.7M |
| Research and development expenses | $12.6M | $10.5M | $8.72M | $7.13M | $5.82M |
| Selling, general and administrative expenses | $19.2M | $17.8M | $13.8M | $12.2M | $10.1M |
| Other expenses | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $31.8M | $28.3M | $22.5M | $19.4M | $15.9M |
| Cost and expenses | $64.2M | $63.3M | $56.1M | $51.6M | $43M |
| Interest income | $1.36M | $1.4M | $2.39M | $1.25M | $10K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $3.39M | $1.36M | $450K | $310K |
| Ebitda | -$-11.74M | -$-900K | $13.8M | $15.1M | $9.85M |
| Operating income | -$-14.15M | -$-4.31M | $10.1M | $13.4M | $7.8M |
| Total other income/expenses, net | $2.41M | $20K | $2.38M | $1.24M | $1.74M |
| Income before tax | -$-11.74M | -$-4.29M | $12.5M | $14.6M | $9.54M |
| Income tax expense | -$-4.61M | -$-380K | -$-20.7M | $60K | $90K |
| Net income | -$-7.13M | -$-3.91M | $33.2M | $14.6M | $9.45M |
| Weighted average shares outstanding | $30.7M | $29.6M | $28.8M | $27.8M | $26M |
| Weighted average diluted shares outstanding | $30.7M | $29.6M | $29.6M | $29.2M | $27.8M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $116.4M | $25.2M | $49.2M | $47.9M | $31.5M |
| Net receivables | $17.5M | $17.8M | $10M | $16.6M | $12.9M |
| Inventory | $41.4M | $42M | $37.5M | $23.9M | $15.1M |
| Total current assets | $184.5M | $88.8M | $97.9M | $89M | $60M |
| Property, plant and equipment, net | $17.8M | $18.6M | $8.99M | $8.88M | $2.12M |
| Goodwill and intangible assets | $20.3M | $21.5M | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $200K | $200K | $150K | $80K |
| Total non-current assets | $62.3M | $59.7M | $30.1M | $9.11M | $2.32M |
| Total assets | $246.7M | $148.5M | $127.9M | $98.1M | $62.3M |
| Accounts payable | $6.75M | $6.73M | $5.33M | $9.21M | $4.2M |
| Short-term debt | $630K | $910K | $470K | $140K | $790K |
| Deferred revenue | $5.19M | $180K | $100K | $130K | $150K |
| Total current liabilities | $17.9M | $15.6M | $10.5M | $16.3M | $11M |
| Long-term debt | $9.26M | $9.92M | $5.73M | $6.16M | $210K |
| Deferred revenue, non-current | $0.00 | $40K | $40K | $30K | $70K |
| Total non-current liabilities | $9.33M | $10M | $5.81M | $6.24M | $330K |
| Capital lease obligations | $0.00 | $9.92M | $5.73M | $6.16M | $210K |
| Total liabilities | $27.2M | $25.6M | $16.3M | $22.5M | $11.3M |
| Common stock | $330K | $300K | $290K | $280K | $270K |
| Retained earnings | -$-30.19M | -$-23.06M | -$-19.15M | -$-52.31M | -$-66.86M |
| Accumulated other comprehensive income (loss) | -$-100K | -$-130K | -$-160K | -$-150K | -$-100K |
| Total equity | $219.5M | $122.9M | $111.6M | $75.6M | $51M |
| Total investments | $0.00 | $200K | $200K | $18M | $80K |
| Total debt | $9.88M | $10.8M | $6.2M | $6.3M | $1.01M |
| Net debt | -$-106.48M | -$-14.4M | -$-42.96M | -$-23.75M | -$-30.48M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | -$-7.13M | -$-3.91M | $33.2M | $14.6M | $9.45M |
| Depreciation and amortization | $2.8M | $3.39M | $1.36M | $450K | $310K |
| Stock-based compensation | $6.76M | $5.16M | $2.52M | $0.00 | $3.01M |
| Change in working capital | -$-1.79M | -$-12.2M | -$-14.38M | -$-7.28M | -$-9.56M |
| Accounts receivable | -$-3.31M | -$-3.04M | $6.79M | -$-3.79M | -$-7.83M |
| Inventory | $10K | -$-2.44M | -$-13.73M | -$-9.47M | -$-6.67M |
| Accounts payable | $990K | -$-710K | -$-3.89M | $5.04M | $1.36M |
| Net cash provided by operating activities | -$-3.31M | -$-7.4M | $1.76M | $10M | $1.51M |
| Investments in property, plant and equipment | -$-2.07M | -$-4.99M | -$-750K | -$-1.36M | -$-420K |
| Acquisitions, net | -$-1.8M | -$-11.07M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-3.87M | -$-16.07M | $17.3M | -$-18.66M | -$-420K |
| Common stock issued | $99.6M | $1.41M | $1.74M | $9.38M | $27.6M |
| Common stock repurchased | -$-2.36M | -$-780K | -$-1.6M | -$-2.06M | -$-430K |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $97.2M | $620K | $140K | $7.32M | $25.8M |
| Net change in cash | $90M | -$-23.93M | $19.1M | -$-1.43M | $26.9M |
| Cash at end of period | $116.5M | $25.2M | $49.2M | $30.1M | $31.5M |
| Operating cash flow | -$-3.31M | -$-7.4M | $1.76M | $10M | $1.51M |
| Capital expenditure | -$-2.07M | -$-4.99M | -$-750K | -$-1.36M | -$-420K |
| Free cash flow | -$-5.38M | -$-12.39M | $1.01M | $8.65M | $1.09M |
Line items
Line items
Line items
About Aehr Test Systems
Aehr Test Systems, founded in 1977 and based in Fremont, California, specializes in the global provision of advanced burn-in and test systems for integrated circuits, encompassing logic, optical, and memory devices. Its extensive product lineup includes the ABTS and FOX-P families of test and burn-in solutions, complemented by specialized components such as the FOX WaferPak Aligner, FOX-XP WaferPak Contactor, FOX DiePak Carrier, and FOX DiePak Loader. The ABTS system is specifically designed for both production and qualification assessments of packaged parts, covering a range of lower and higher power logic devices, as well as various memory types. For more complex integrated circuits like memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices, the FOX-XP and FOX-NP systems facilitate burn-in and functional testing at both the wafer and individual die/module levels. Aehr's FOX-CP system offers a compact, single-wafer solution for verifying the reliability of logic, memory, and photonic devices. A distinguishing offering, the WaferPak Contactor, features an exclusive full-wafer probe card, accommodating wafers up to 300mm, which enables semiconductor manufacturers to conduct comprehensive wafer-level testing and burn-in on Aehr's FOX platforms. Furthermore, the DiePak Carrier provides a reusable, temporary packaging medium, empowering IC manufacturers to complete final testing and burn-in processes for bare die and modules.
- CEO
- Gayn Erickson
- Employees
- 136
- Beta
- 3.18
Explore
Frequently asked questions
What is the intrinsic value of Aehr Test Systems (AEHR)?
Aehr Test Systems (AEHR) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AEHR undervalued?
AEHR trades at a price of $39.84 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.